Startseite>>Signaling Pathways>> PROTAC>> E3 Ligase Ligand-Linker Conjugate>>Thalidomide 4'-oxyacetamide-PEG4-amine

Thalidomide 4'-oxyacetamide-PEG4-amine

Katalog-Nr.GC50463

Thalidomide 4'-Oxyacetamid-PEG4-Amin, ein synthetisiertes E3-Ligase-Ligand-Linker-Konjugat, das den auf Thalidomid basierenden Cereblon-Liganden und einen Linker enthÄlt, kann bei der Synthese von PROTACs verwendet werden.

Products are for research use only. Not for human use. We do not sell to patients.

Thalidomide 4'-oxyacetamide-PEG4-amine Chemische Struktur

Cas No.: 2245697-85-0

Größe Preis Lagerbestand Menge
25 mg
148,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Functionalized cereblon ligand for PROTAC® research and development; incorporates an E3 ligase ligand plus a PEG linker ready for conjugation to a target protein ligand. Part of a range of functionalized tool molecules for PROTAC R&D. This product has been recently renamed. The previous name for this product was Thalidomide - linker 2 PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.

Winter et al (2015) Drug development. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348 1376 PMID:25999370 |Salami et al (2017) Waste disposal-An attractive strategy for cancer therapy. Science 355 1163 PMID:28302825

Bewertungen

Review for Thalidomide 4'-oxyacetamide-PEG4-amine

Average Rating: 5 ★★★★★ (Based on Reviews and 12 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Thalidomide 4'-oxyacetamide-PEG4-amine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.